协同致死在肾细胞癌中的研究进展  

Advances in synthetic lethality for renal cell carcinoma

作　　者：张鹏[1] 简文刚 张诚[1,2] ZHANG Peng;JIAN Wengang;ZHANG Cheng(Department of Urology,the First Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150001,China;Department of Urology,the Fourth Affiliated Hospital of Zhejiang University School of Medicine,Zhejiang Yiwu 322000,China)

机构地区：[1]哈尔滨医科大学附属第一医院泌尿外科,黑龙江哈尔滨150001 [2]浙江大学医学院附属第四医院泌尿外科,浙江义乌322000

出　　处：《现代肿瘤医学》2021年第22期4032-4035,共4页Journal of Modern Oncology

基　　金：国家自然科学基金项目(编号:81872084)。

摘　　要：肾细胞癌(renal cell carcinoma,RCC)是常见的癌症之一,常采用手术结合靶向和免疫治疗为主的综合治疗。但因靶向治疗的客观缓解率有限和免疫治疗的耐药性增加等问题,RCC亟需全新的治疗手段。目前协同致死理论在RCC的研究领域中取得重大突破,特别是在高突变率的基因包括VHL、PBRM1、SETD2等的RCC中,许多研究证实RCC中存在切实可行的协同致死伴侣。此外协同致死筛选方法及液体活检的开展,将为RCC患者精准化、个体化治疗提供新的思路。本文就协同致死在RCC方面的研究进展和机遇挑战进行综述。Renal cell carcinoma(RCC)is one of the common cancers,and it is often treated by a comprehensive treatment that is based on surgery combined with targeted therapy and immunotherapy.However,due to problems like the limited objective response rate of targeted therapy,the increasing drug resistance of immunotherapy and so on,RCC is in urgent need of new treatment approaches.At present,synthetic lethality has been made a major breakthrough in the research field of RCC,especially in RCC with high mutation rate including VHL,PBRM1,SETD2 and so on.Plenty of studies have confirmed that there are feasible synthetic lethality partners in RCC.In addition,the development of the synthetic lethal screening approaches and liquid biopsy will provide new ideas for precision and individual treatment for RCC patients.This paper reviews the advances,opportunities and challenges of synthetic lethality effect on RCC.

关 键 词：协同致死 肾细胞癌 肿瘤抑癌基因 免疫治疗 表观遗传学 

分 类 号：R737.11[医药卫生—肿瘤]